Vertex Pharmaceuticals Incorporated VRTX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 12.95B | 12.59B | 12.20B | 11.97B | 11.69B |
| Total Other Revenue | 0.00 | 0.00 | 20.70M | 30.70M | 30.70M |
| Total Revenue | 12.95B | 12.59B | 12.22B | 12.00B | 11.72B |
| Cost of Revenue | 5.85B | 5.67B | 5.57B | 5.56B | 5.54B |
| Gross Profit | 7.10B | 6.92B | 6.65B | 6.44B | 6.18B |
| SG&A Expenses | 2.20B | 2.01B | 1.85B | 1.75B | 1.64B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.06B | 7.68B | 7.42B | 7.31B | 7.19B |
| Operating Income | 4.89B | 4.91B | 4.80B | 4.69B | 4.54B |
| Income Before Tax | 4.76B | 5.27B | 5.17B | 4.64B | 4.45B |
| Income Tax Expenses | 783.20M | 869.30M | 827.40M | 690.00M | 773.60M |
| Earnings from Continuing Operations | 3.98K | 4.41K | 4.34K | 3.95K | 3.68K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.98B | 4.41B | 4.34B | 3.95B | 3.68B |
| EBIT | 4.89B | 4.91B | 4.80B | 4.69B | 4.54B |
| EBITDA | 5.10B | 5.10B | 4.98B | 4.87B | 4.71B |
| EPS Basic | 15.66 | 17.32 | 17.01 | 15.47 | 14.32 |
| Normalized Basic EPS | 13.16 | 13.29 | 12.90 | 12.61 | 12.17 |
| EPS Diluted | 15.54 | 17.18 | 16.86 | 15.33 | 14.18 |
| Normalized Diluted EPS | 13.07 | 13.18 | 12.79 | 12.50 | 12.06 |
| Average Basic Shares Outstanding | 1.02B | 1.02B | 1.02B | 1.02B | 1.03B |
| Average Diluted Shares Outstanding | 1.02B | 1.03B | 1.03B | 1.03B | 1.04B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |